Binding of heparin-induced thrombocytopenia (HIT) sera to PF4 variants
Patients with HIT . | WT . | P37N . | T38Q . | A39V . | L41V . | N47D . | NAP2 . |
---|---|---|---|---|---|---|---|
Sensitive (n = 5) | 3.10 ± 0.56 | 0.60 ± 0.31 | 1.56 ± 1.08† | 2.51 ± 0.99 | 1.67 ± 1.22 | 1.52 ± 1.10* | 0.34 ± 0.31 |
A405 <1.0 | |||||||
Intermediate (n = 9) | 3.41 ± 0.40 | 1.98 ± 0.34 | 2.42 ± 1.06 | 3.12 ± 0.70 | 1.94 ± 1.10 | 3.12 ± 1.18 | 0.61 ± 0.42 |
A405 ≥1.0 to <2.5 | |||||||
Insensitive (n = 9) | 3.66 ± 0.10 | 2.99 ± 0.40 | 3.45 ± 0.29† | 3.27 ± 1.12 | 1.91 ± 1.44 | 2.88 ± 1.10* | 0.45 ± 0.38 |
A405 ≥2.5 | |||||||
Total (n = 23) | 3.44 ± 0.41 | 2.06 ± 0.98 | 2.64 ± 1.10 | 3.04 ± 0.97 | 1.87 ± 1.22 | 2.64 ± 1.27 | 0.48 ± 0.38 |
Patients with HIT . | WT . | P37N . | T38Q . | A39V . | L41V . | N47D . | NAP2 . |
---|---|---|---|---|---|---|---|
Sensitive (n = 5) | 3.10 ± 0.56 | 0.60 ± 0.31 | 1.56 ± 1.08† | 2.51 ± 0.99 | 1.67 ± 1.22 | 1.52 ± 1.10* | 0.34 ± 0.31 |
A405 <1.0 | |||||||
Intermediate (n = 9) | 3.41 ± 0.40 | 1.98 ± 0.34 | 2.42 ± 1.06 | 3.12 ± 0.70 | 1.94 ± 1.10 | 3.12 ± 1.18 | 0.61 ± 0.42 |
A405 ≥1.0 to <2.5 | |||||||
Insensitive (n = 9) | 3.66 ± 0.10 | 2.99 ± 0.40 | 3.45 ± 0.29† | 3.27 ± 1.12 | 1.91 ± 1.44 | 2.88 ± 1.10* | 0.45 ± 0.38 |
A405 ≥2.5 | |||||||
Total (n = 23) | 3.44 ± 0.41 | 2.06 ± 0.98 | 2.64 ± 1.10 | 3.04 ± 0.97 | 1.87 ± 1.22 | 2.64 ± 1.27 | 0.48 ± 0.38 |
Binding studies of 23 HIT sera to PF4 variants complexed to heparin, each with an A405 to wild-type PF4/heparin of >2.5. Subgroups of patients were classified by reactivity to mutations involving the third domain of PF4. Sera losing reactivity to third-domain mutations with A405 <1.0 were defined as sensitive, those retaining activity with A405 >2.5 as insensitive, and those with A405 ≥1.0 to ≤2.5 as intermediate in reactivity. The mean ± 1 SD is shown.
P < .05;
P < .01.